Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL999 in Acute Myeloid Leukemia
NCT00322673Phase 2Terminated
- Sponsor
- Symphony Evolution
- Start
- May 2006
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of xl999 in acute myeloid leukemia (AML), sponsored by Symphony Evolution. Primary endpoints: Hematologic and cytogenetic response rate and Safety and tolerability. Started May 2006; status: terminated.
02
Drugs
xl999
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00322673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322673.